BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price lowered by Citigroup from $93.00 to $81.00 in a research report released on Wednesday morning, Benzinga reports. The firm currently has a neutral rating on the biotechnology company’s stock. Other equities analysts have also issued reports about the stock. Sanford C. Bernstein cut their target […]

William Blair cut shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from an outperform rating to a market perform rating in a research note issued to investors on Wednesday morning, Marketbeat reports. A number of other research analysts have also recently issued reports on BMRN. Raymond James reiterated an “outperform” rating and issued a $79.00 […]